June 15, 2020

Akili announces FDA clearance of EndeavorRx™ for children with ADHD

Akili Interactive announced this week that the FDA has granted clearance for the company’s EndeavorRx as a prescription treatment for children with attention-deficit/hyperactivity disorder (ADHD).

Delivered through a captivating video game experience, EndeavorRx is indicated to improve attention function as measured by computer-based testing in children ages 8-12 years old with primarily inattentive or combined-type ADHD, who have a demonstrated attention issue.

The MLSC previously supported Akili through its Universal Partnership program, which aimed to create global partnerships between life science organizations, while enabling scientific and commercial breakthroughs and to fuel economic development in the Commonwealth.